Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
100%
Tumor Protein p53 (TP53)
100%
Epidermal Growth Factor Receptor
100%
Programmed Death-ligand 1 (PD-L1)
100%
Vulvar Cancer
100%
Immunohistochemical Profile
100%
CD274
100%
Lymph Node Metastasis
85%
Vulvar Squamous Cell Carcinoma
57%
Overall Survival
42%
Primary Tumor
42%
Tumor Recurrence
42%
Tumor-node-metastasis
42%
Tumor
28%
Tumor Progression
28%
High-risk Human Papillomavirus (HR-HPV)
28%
Carcinoma
28%
Recurrent Disease
28%
Therapeutic Potential
14%
Molecular Entity
14%
Immunohistochemistry
14%
Targeted Therapy
14%
Prognostic Biomarker
14%
Surface Expression
14%
Multivariable Cox Regression
14%
Cox Regression Analysis
14%
New Agents
14%
Tissue Microarray
14%
Immunoexpression
14%
FIGO Stage
14%
High-risk Human Papillomavirus DNA
14%
P53 Expression
14%
Epidermal Growth Factor Receptor Expression
14%
Kaplan-Meier Estimator
14%
Biomarker Expression
14%
Programmed Cell death-1/programmed Cell Death Ligand 1
14%
Retesting
14%
Medicine and Dentistry
Protein P53
100%
Epidermal Growth Factor Receptor
100%
P16
100%
Vulvar Cancer
100%
Programmed Death-Ligand 1
100%
Tumor Protein
100%
Cyclin Dependent Kinase Inhibitor 2A
100%
Lymph Node Metastasis
85%
Squamous Cell Carcinoma
57%
Biological Marker
42%
Overall Survival
42%
Primary Tumor
42%
Recurrent Disease
42%
Tumor Recurrence
42%
Wart Virus
42%
Carcinoma
28%
Tumor Progression
28%
Targeted Therapy
14%
Tumor
14%
Neoplasm
14%
Proportional Hazards Model
14%
Immunohistochemistry
14%
Tissue Microarray
14%
Receptor Expression
14%
Programmed Cell Death
14%
Programmed Death 1 Ligand 1
14%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Cyclin Dependent Kinase Inhibitor 2A
100%
Protein P53
100%
Epidermal Growth Factor Receptor
100%
Tumor Protein
100%
Lymph Node Metastasis
85%
Squamous Cell Carcinoma
57%
Biological Marker
42%
Overall Survival
42%
Primary Tumor
42%
Recurrent Disease
42%
Human Papillomavirus
42%
Tumor Recurrence
42%
Carcinoma
28%
Tumor Growth
28%
Neoplasm
14%
Programmed Cell Death
14%
Programmed Death 1 Ligand 1
14%